Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Algitrin is a combination analgesic and muscle relaxant medication developed and marketed by Sanfer (Invekra). It typically contains ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), and methocarbamol, a central nervous system (CNS) depressant. Ibuprofen exerts its effects by inhibiting the cyclooxygenase enzymes COX-1 and COX-2, thereby reducing the synthesis of prostaglandins that mediate pain and inflammation. Methocarbamol acts as a muscle relaxant through general CNS depression, specifically by inhibiting polysynaptic reflexes, although its exact molecular target remains uncharacterized. The product is available in various forms, including tablets, gels, and syrups, and is primarily indicated for the relief of musculoskeletal pain, muscle spasms, and associated inflammatory conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ibuprofen + methocarbamol (Sanfer).